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Many neuropsychiatric symptoms of fragile X syn-
drome (FXS) are believed to be a consequence of
altered regulation of protein synthesis at synapses.
We discovered that lovastatin, a drug that is widely
prescribed for the treatment of high cholesterol,
can correct excess hippocampal protein synthesis
in the mouse model of FXS and can prevent one of
the robust functional consequences of increased
protein synthesis in FXS, epileptogenesis. These
data suggest that lovastatin is potentially disease
modifying and could be a viable prophylactic treat-
ment for epileptogenesis in FXS.
INTRODUCTION
Seizures and EEG abnormalities were noted in some of the
earliest studies of autism (Kanner, 1943; Tuchman et al., 2010),
and it is now appreciated that approximately 30% of the ASD
population have epilepsy. The etiologic heterogeneity of autism
and epilepsy have made it difficult to understand the molecular
mechanisms linking the two disorders. One approach is to
focus on syndromic disorders that have a known genetic etiology
and valid animal models. In the current study, we have used
a mouse model of fragile X syndrome (FXS), a single-gene
developmental disorder characterized by increased incidence
of both autism and epilepsy (Berry-Kravis, 2002; Musumeci
et al., 1999). The Fmr1/y (knockout [KO]) mouse exhibits robust
epilepsy phenotypes, both in vitro, as measured by ictal-like
discharges in hippocampal slices and neocortical hyperexcit-
ability, and in vivo, as measured by increased susceptibility to
audiogenic seizures (AGS) (Yan et al., 2004).
The FMR1 gene encodes the translational repressor fragile
X mental retardation protein (FMRP). Pathological changes
observed in FXS are believed to stem in part from an elevation
of basal protein synthesis downstream of an extracellular
signal-regulated kinase (ERK1/2) signaling pathway (Bhakar
et al., 2012). ERK1/2 is a key member of the larger MAP kinase
(MAPK) signaling pathway, which is involved in regulation ofmultiple biochemical processes including the initiation of cap-
dependent translation. At the head of this intracellular cascade
lies the small GTPase Ras. The Ras/MAPK pathway is a major
regulator of cell growth, and thus a strong inhibitor of Ras-
ERK1/2 would have deleterious consequences on the devel-
oping brain. However, a previous study reported that lovastatin,
an HMG-CoA reductase inhibitor in widespread use for the
treatment of hypercholesterolemia in both children and adults,
could correct cognitive deficits caused by excess Ras activity
in the mouse model of neurofibromatosis type 1 (Li et al.,
2005). Lovastatin can achieve a mild reduction in Ras-ERK1/2
activation by interfering with the recruitment of Ras to the
membrane, a process that is required to transition from the
inactive guanosine diphosphate (GDP)-bound form to the active
guanosine triphosphate (GTP)-bound form (Kloog et al., 1999;
Schafer et al., 1989). The interaction of Ras with the membrane
requires the posttranslational addition of a farnesyl group to the
C terminus and lovastatin inhibits Ras farnesylation by targeting
the upstream mevalonate pathway (Figure 1A) (Li et al., 2005;
Mendola and Backer, 1990; Schafer et al., 1989). We therefore
wondered whether lovastatin could prevent pathological
changes in FXS that lie downstream of excessive ERK-mediated
protein synthesis and contribute to epileptogenesis. Unless
otherwise stated, we tested lovastatin in male KO and wild-
type (WT) mice in the C57BL/6 background.RESULTS
Lovastatin Normalizes Excessive Protein Synthesis
in the Fmr1 KO
We showed previously that partial inhibition of ERK1/2 was suffi-
cient to restore normal levels of protein synthesis in the Fmr1
KO hippocampus (Osterweil et al., 2010). To determine whether
reduction of Ras signaling has the same effect, we used farnesyl
thiosalicylic acid (FTS), which dislodges Ras from the membrane
(Figure 1A) (Weisz et al., 1999). Hippocampal slices were
prepared from juvenile Fmr1 KO and WT mice and preincubated
in 25, 50 mM FTS or vehicle for 30 min. Protein synthesis was
measured for another 30 min via incorporation of a 35S-labeled
methionine/cysteine (35S-Met/Cys) mix. We found that 50 mM
FTS reduces protein synthesis in the Fmr1 KO down toWT levelsNeuron 77, 243–250, January 23, 2013 ª2013 Elsevier Inc. 243
Figure 1. Lovastatin Inhibits Ras-ERK1/2 Signaling, Normalizes
Excessive Protein Synthesis, and Corrects Exaggerated mGluR-
LTD in the Fmr1 KO Hippocampus
(A) Model of the mechanism by which lovastatin and FTS reduce Ras-ERK1/2
activation and normalize protein synthesis in the Fmr1 KO. (B) Application of
FTS corrects excessive protein synthesis in the Fmr1KO (WT: veh 100%±4%,
25 mM104%±5%; 50 mM90%±2%; KO: veh 113%±4%, 25 mM101%±5%;
50 mM 94% ± 4%; ANOVA treatment *p = 0.0017; WT versus KO veh *p =
0.041, KO veh versus 50 mM *p = 0.00002; n = 15). A small but significant
reduction of protein synthesis is also observed with 50 mM FTS in WT (*p =
0.0316). (C) Lovastatin inhibits Ras activation in hippocampal slices (WT: veh
100% ± 11%, 10 mM 87% ± 14%; 50 mM 61% ± 12%; KO: veh 96% ± 8%,
10 mM 89% ± 8%; 50 mM 61% ± 9%; ANOVA treatment *p = 0.0266; WT *p =
0.039, KO *p = 0.015; n = 6). (D) Lovastatin downregulates ERK1/2 (WT: veh
100% ± 7%, 10 mM 94% ± 8%; 50 mM 84% ± 5%; KO: veh 97% ± 5%, 10 mM
90% ± 6%; 50 mM 78% ± 5%; ANOVA treatment *p = 0.0037; WT *p = 0.035,
KO *p = 0.008; n = 15). (E) Lovastatin normalizes protein synthesis in Fmr1 KO
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244 Neuron 77, 243–250, January 23, 2013 ª2013 Elsevier Inc.(WT versus KO veh *p = 0.041, KO veh versus 50 mM FTS *p =
0.00002) (Figure 1B).
We next asked whether lovastatin could inhibit Ras in our
slices as has been shown in other systems. Hippocampal slices
were prepared from WT and Fmr1 KO, then incubated with
10–50 mM lovastatin or vehicle. GTP-bound Ras was isolated
using a glutathione S-transferase (GST) pull-down assay and
compared to total Ras. Our results show that 50 mM lovastatin
significantly reduces the amount of active Ras in both WT and
Fmr1 KO hippocampal slices (WT *p = 0.039, KO *p = 0.015)
(Figure 1C).
Western blot analysis revealed that 50 mM lovastatin also
significantly reduces ERK1/2 activation in both WT and Fmr1
KO slices (WT *p = 0.035, KO *p = 0.008) (Figure 1D). To examine
the consequence of this modest reduction in ERK1/2 activity
on hippocampal protein synthesis, we performed metabolic
labeling on WT and Fmr1 KO slices in the presence of 10–
50 mM lovastatin. We found that inhibition of the Ras-ERK1/2
pathway by 50 mM lovastatin is sufficient to restore WT levels
of protein synthesis in hippocampal slices from the Fmr1 KO
(WT versus KO veh *p = 0.019, KO veh versus 50 mM *p =
0.011) (Figure 1E). Consistent with previous findings, there was
no difference in basal levels of Ras and ERK1/2 in the Fmr1 KO
hippocampus, suggesting that the excessive protein synthesis
in the Fmr1 KO is due to a hypersensitivity to, not hyperactivation
of, the Ras-ERK1/2 signaling pathway (Osterweil et al., 2010). To
see whether the effects of FTS and lovastatin on protein
synthesis might be due to inhibition of the homologous GTPase
Rheb instead of Ras (Makovski et al., 2012), we measured the
phosphorylation (activation) of p70S6 kinase (p70S6K) and S6
ribosomal protein (see Supplemental Information available on-
line). We failed to detect changes in these downstream markers
of Rheb activity (Figures S1 and S2), suggesting that inhibition
of Rheb is not likely to be the mechanism of action for FTS or
lovastatin in our preparation.
An electrophysiological signature of altered hippocampal
protein synthesis in the Fmr1 KO mouse is exaggerated long-
term synaptic depression (LTD) induced by activation of metab-
otropic glutamate receptor 5 (mGluR5) (Huber et al., 2002). We
therefore examined the effect of lovastatin on LTD induced
by the mGluR5 agonist 3,5-dihydroxyphenylglycine (DHPG) inhippocampal slices (WT: veh 100% ± 5%, 10 mM 103% ± 4%; 50 mM 88% ±
5%; KO: veh 119% ± 6%, 10 mM 115% ± 7%; 50 mM 91% ± 4%; ANOVA
genotype x treatment *p = 0.0332; WT versus KO veh *p = 0.019, KO veh
versus 50 mM *p = 0.011; n = 11). (F) LTD was induced with 50 mM R,S-DHPG
and extracellular recordings were performed in area CA1. In the presence of
vehicle, greater LTD is observed in the Fmr1 KO versus WT (WT veh 72.5% ±
2.5%, KO veh 57.5% ± 2.5%, *p = 0.005, n = 9–10). Fifty micromolar lovastatin
significantly reduces LTD magnitude in the Fmr1 KO to WT levels (WT
lova 72.7% ± 4.4%, KO lova 74.5% ± 3.4%; KO veh versus lova *p < 0.001,
n = 11–13) but has no significant effect on LTD in the WT (WT veh versus
lova p = 0.869). Field potential traces are averages of all experiments and
were taken at times indicated by numerals; scale bars represent 0.5 mV, 5 ms.
(G) Lovastatin significantly reduces LTD magnitude in the Fmr1 KO to WT
levels (ANOVA genotype 3 treatment *p = 0.021). LTD magnitude was
assessed by a comparison of the averaged last 5 min pre-DHPG and the last
5 min of recordings (minutes 55–60 post-DHPG). n = animals. Error bars
represent SEM.
Figure 2. Lovastatin Blocks mGluR-Mediated Epileptiform Bursting
in the Fmr1 KO Hippocampus
Intracellular recordings were performed on CA3 pyramidal neurons in WT and
Fmr1 KO hippocampal slices. (A) In WT slices, 50 mM R,S-DHPG leads to
bursting from CA3 neurons, which progresses to epileptiform discharges by
60 min. This epileptiform activity is prevented by a 60 min pretreatment with
50 mM lovastatin. (B) Addition of lovastatin after 60 min post-DHPG did not
affect the duration of epileptiform discharges. (C) Mean epileptiform burst
durations fromWT slices under the following conditions: at 60 min post-DHPG
(4.359 ± 0.14 s; n = 125 discharges, six slices from six animals), lovastatin-
pretreated (0.618 ± 0.03 s; n = 545 discharges, 12 slices from seven animals),
and lovastatin after DHPG (4.066 ± 0.15 s; n = 124 discharges, five slices from
five animals). Slices pretreated with lovastatin showed significant reduction in
burst duration compared to vehicle-pretreated slices (*p = 0.0000218), while
therewas no significant difference in burst duration between DHPG 60min and
lovastatin after DHPG (p = 0.072). (D) In Fmr1 KO slices, synaptic mGluR
activation by spontaneous activity in bicuculline induces prolonged epilepti-
form discharges, which are blocked with 60 min pretreatment with 50 mM
lovastatin. (E) In contrast to Fmr1 KO slices, bicuculline fails to induce pro-
longed epileptiform discharges inWT slices. (F) Plot of mean epileptiform burst
durations from Fmr1 KO slices 60 min after bicuculline ±50 mM lovastatin and
WT slices 60 min after bicuculline. Fmr1 KO slices pretreated with lovastatin
showed significant reduction in burst duration (0.528 ± 0.01 s; n = 182
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incubated in vehicle or 50 mM lovastatin, extracellular field
potentials were recorded in area CA1 in response to Schaffer
collateral stimulation, and mGluR-LTD was induced with
a 5 min bath application of 50 mM DHPG with the experimenter
blind to genotype and treatment. We found that lovastatin
corrects the exaggerated mGluR-LTD observed in the Fmr1
KO to WT levels (WT veh versus KO veh *p = 0.005, KO veh
versus lova *p < 0.001) but had no significant effect on mGluR-
LTD in the WT (WT veh versus lova p = 0.869) (Figures 1F and
1G). These electrophysiological findings corroborate the bio-
chemical results and support the conclusion that lovastatin can
correct excessive protein synthesis in the Fmr1 KO.
Lovastatin Prevents mGluR-Induced Epileptogenesis
in Hippocampal Slices
Previous studies in slices of hippocampal area CA3 have shown
that a lasting consequence of mGluR5- and ERK-mediated
protein synthesis is the generation of epileptiform activity (Merlin
et al., 1998; Zhao et al., 2004). We therefore investigated the
effect of lovastatin in this model of epileptogenesis. Intracellular
recordings were made from CA3 pyramidal cells in WT hippo-
campal slices ±1 hr preincubation with 50 mM lovastatin.
Single-cell behavior and network discharge behavior can be
differentiated in these intracellular recordings in that the occur-
rence, rhythm, and duration of network discharges are not
affected by depolarizing or hyperpolarizing the recorded cell
(see Taylor et al., 1995). In control slices, addition of DHPG first
elicited short (500 ms) synchronized discharges, which gradu-
ally extended to reach an average duration of 4.359 ± 0.14 s at
60 min (Figure 2A). Preincubation with 50 mM lovastatin signifi-
cantly reduced the average duration of synchronized discharges
to 0.618 ± 0.03 s at 60 min (*p = 0.0000218; Figures 2A and 2C).
These results suggest that lovastatin is sufficient to block the
induction of mGluR-mediated epileptiform activity in hippo-
campal slices.
The epileptiform discharges observed after sustained DHPG
application persist after the agonist is removed. This mainte-
nance phase is not affected by inhibition of protein synthesis
or ERK1/2, suggesting that translation plays a specific role in
epileptogenesis (Zhao et al., 2004). Similarly, exposure of slices
to 50 mM lovastatin 60 min after DHPG had no effect on average
burst duration (average duration 4.066 ± 0.15 s; p = 0.072;
Figures 2B and 2C). These results are consistent with the action
of lovastatin as an inhibitor of ERK-mediated protein synthesis
(Merlin et al., 1998).
In the Fmr1 KO, spontaneous activity is sufficient to elicit
epileptiform discharges in hippocampal CA3, suggesting a
hypersensitive response to mGluR5-ERK1/2 activation (Chuang
et al., 2005). Thus, unlike WT slices, which require DHPG todischarges; ten slices from five animals) compared to vehicle-pretreated slices
(2.227 ± 0.13 s; n = 90 discharges; eight slices from six animals; *p = 0.000022),
while there was no significant difference in burst duration between lovastatin-
pretreated Fmr1 KO slices and bicuculline-treated WT slices (0.537 ± 0.01 s;
n = 88 discharges; five slices from five animals; p = 0.995). Insets indicate
summary frequency histograms of synchronized discharges in each experi-
mental condition. Error bars represent SEM.
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Figure 3. Lovastatin Reduces Excitability in the Fmr1 KO Visual
Cortex
(A) Extracellular recordings were performed in layer 5 of visual cortical slices.
Trains of action potentials (APs) were evoked with 60 trials of white matter
stimulation. Responses were collected in ACSF plus vehicle, then ACSF plus
50 mM lovastatin. (B and C) Representative traces and raster plots of record-
ings fromWT (B) and Fmr1 KO (C). Prolonged firing in the Fmr1 KO is corrected
with 50 mM lovastatin application. (D) Lovastatin significantly reduces firing in
Fmr1 KO but not WT visual cortical slices. (E) The mean number of action
potentials is significantly higher in Fmr1 KO slices versusWT slices, and 50 mM
lovastatin restores normal firing to the Fmr1 KO slices (WT veh 100% ± 20%,
WT lova 103% ± 20%, KO veh 203% ± 44%, KO lova 113% ± 29%; ANOVA
genotype x treatment *p = 0.0022; WT versus KO veh *p = 0.0258, KO veh
versus lova *p = 0.0001, WT veh versus lova p = 0.8412; WT n = 10 slices from
five animals, KO n = 19 slices from nine animals). Error bars represent SEM.
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in Fmr1 KO slices simply by applying the GABA-A receptor
antagonist bicuculline to increase recurrent network activity
(Bianchi et al., 2009). Intracellular recordings were therefore
performed on bicuculline-treated Fmr1 KO slices ±1 hr preincu-
bation of 50 mM lovastatin. In untreated KO slices, bicuculline
elicited short (<1 s) synchronized discharges that increased
progressively in duration over the course of 60 min (average
duration 2.227 ± 0.13 s at 60 min). This progression was
prevented by preincubation in lovastatin (Figures 2D and 2F).
The average burst duration of Fmr1 KO slices in lovastatin
(0.528 ± 0.01 s at 60 min) was not significantly different from
discharges elicited by bicuculline in the WT (0.537 ± 0.01 s;
p = 0.995; Figures 2E and 2F). These results show that acute246 Neuron 77, 243–250, January 23, 2013 ª2013 Elsevier Inc.application of lovastatin blocks epileptogenesis in the Fmr1 KO
hippocampus.
Lovastatin Dampens Hyperexcitability in the Fmr1 KO
Visual Cortex
Increased excitability has been observed in the neocortex of
the Fmr1 KO. This phenotype is caused by specific changes in
excitatory synaptic transmission and neuronal membrane excit-
ability and can be rescued by inhibition or reduced expression of
mGluR5 (Hays et al., 2011). To investigate whether lovastatin
could similarly reduce cortical hyperexcitability, we prepared
acute slices from visual cortex and measured persistent activity
in layer 5 pyramidal neurons. Spiking activity was evoked with
electrical stimulation of the underlying white matter every 30 s
for a total number of 60 trials in artificial cerebrospinal fluid
(ACSF) plus vehicle, followed by 60 trials in ACSF plus 50 mM
lovastatin (Figure 3A). We found that the barrage of action
potentials evoked by stimulation of white matter is significantly
longer in the Fmr1 KO (Figures 3B and 3C) but is reduced to
WT levels by the application of 50 mM lovastatin (Figures 3B
and 3C). Analysis of the total number of action potentials evoked
revealed a significant dampening effect of lovastatin in Fmr1 KO
but not WT slices (WT versus KO veh *p = 0.0258, KO veh versus
lova *p = 0.0001; Figures 3D and 3E). These results suggest
that lovastatin corrects the hyperexcitability in the Fmr1 KO
visual cortex.
Lovastatin Corrects AGS in the Fmr1 KO
We next tested whether lovastatin could ameliorate AGS
observed in the Fmr1 KO in vivo. Fmr1 KO and WT mice were
injected intraperitoneally (i.p.) with 30 mg/kg lovastatin and, after
1 hr, exposed to a 130 dB stimulus for 2 min. Four stages of
increasing AGS severity were scored: wild running, clonic
seizure, tonic seizure, or death (Osterweil et al., 2010; Yan
et al., 2004). Vehicle-treated Fmr1KOmice exhibited a 74% inci-
dence of AGS, and no seizures were observed in vehicle-treated
WT mice (WT versus KO *p = 0.0002). Acute injection of lova-
statin reduced the incidence of AGS to 28% in the Fmr1 KO
(KO veh versus lov *p = 0.009) and significantly lessened the
severity (Figure 4A). A higher dose of 100 mg/kg lovastatin
showed a similar reduction in AGS incidence (KO veh versus
lov 85% to 23%; *p = 0.005) and severity (KO veh versus lov
*p = 0.015).
To determine whether the effect of lovastatin on AGS suscep-
tibility is independent of the genetic background, we performed
another set of experiments using Fmr1 KO mice in the seizure
prone FVB strain. Consistent with previous studies, we observed
an 85% incidence of AGS in vehicle-treated Fmr1 KO FVB mice
(Yan et al., 2004), which was significantly higher than the 11%
incidence observed in vehicle-treated WT mice (*p = 0.002).
Interestingly, Fmr1 KO FVB mice injected with 30 mg/kg lova-
statin still exhibit a 64% incidence of AGS incidence, which is
not significantly different from the vehicle-treated group (p =
0.357). The severity of AGS is similarly unaffected by this
treatment (p = 0.862) (Figure 4B).
Previous work has shown that higher doses of mGluR5
inhibitors are required to reduce AGS in Fmr1 KO mice bred
on the FVB/NJ background versus the C57BL/6J 3 FVB/NJ
Figure 4. Lovastatin Significantly Reduces AGS Incidence and Severity in the Fmr1 KO
Fmr1KO andWTmice on the C57BL/6 (A,C, and D) or FVB (B) backgrounds were treated as indicated, tested for AGS, and scored for wild running, clonic seizure,
tonic seizure, and death. (A) Injection of 30mg/kg lovastatin acid significantly reduces AGS incidence in the Fmr1 KO on the C57BL/6 background (*p = 0.009; n =
18–19). Pie charts show a significant shift in the severity distribution of Fmr1 KO mice treated with vehicle versus 30 mg/kg lovastatin (WT versus KO veh *p =
0.002,WT versus KO lov p = 0.999; KO veh versus lov *p = 0.041). Injection of a higher 100mg/kg dose of lovastatin also significantly reduces AGS incidence (*p =
0.005; n = 13) and attenuates AGS severity (KO veh versus lov *p = 0.015; WT versus KO veh. *p = 0.04; WT versus KO lov p = 0.999) in Fmr1 KO mice on the
C57BL/6 background. (B) In Fmr1 KO mice bred on the FVB background, injection of 30 mg/kg lovastatin does not significantly reduce AGS incidence (KO veh
85%, KO lov 64%, p = 0.357) or severity (KO veh versus lov p = 0.862); however, a higher dose of 100 mg/kg lovastatin significantly reduces both AGS incidence
(KO veh 82%, KO lov 21%, *p = 0.005; n = 11–14) and severity (KO veh versus lov *p = 0.022; WT versus KO veh *p = 0.016; WT versus KO lov p = 0.999). (C)
Injection of 30 mg/kg lovastatin in the lactone form significantly reduces AGS incidence (*p = 0.009; n = 15) and severity (KO veh versus lov *p = 0.009; WT versus
KO veh *p = 0.005; WT versus KO lov p = 0.999) in Fmr1 KO mice. (D) Feeding of 0.01% lovastatin chow for 48 hr significantly reduces AGS incidence (KO con
71%, KO lov 25%, *p = 0.003; n = 21–24) and severity (KO veh versus lov *p = 0.016;WT versus KO veh *p = 0.0001;WT versus KO lov p = 0.461) in Fmr1 KOmice.
n = animals.
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lovastatin metabolism has been observed between different
mouse strains (Gegg et al., 2005). Based on this literature, we
repeated our experiments using a higher dose of lovastatin.
The results show that an increased dose of 100 mg/kg lova-
statin significantly lowers AGS incidence (KO veh 82%, KO
lov 21%, *p = 0.005) and reduces AGS severity (KO veh versus
lov *p = 0.022) in FVB Fmr1 KO mice (Figure 4B). Thus,
although the effective dose range differs, lovastatin is effective
in correcting AGS in Fmr1 KO mice bred on multiple back-
ground strains.
For human use, lovastatin is administered as a prodrug in its
lactone form, which is metabolized into an active conformation
(lovastatin acid) (Lambert et al., 1996). We therefore wished to
confirm that lovastatin lactone could also reduce AGS incidence
and severity in the Fmr1 KO. Consistent with our previousresults, we found that lovastatin lactone (30 mg/kg) significantly
reduces AGS incidence from 73% to 20% (*p = 0.009) and
reduces AGS severity (KO veh versus lov *p = 0.009) in the
Fmr1 KO (Figure 4C).
We alsowanted to verify that oral administration could similarly
correct AGS in the Fmr1KO. To address this question, we fedWT
and Fmr1 KO mice standard rodent chow supplemented with
0.01% lovastatin, which corresponds to a dose of 10 mg/kg/
day (Yamada et al., 2000). After a 48 hr exposure to either lova-
statin chow or control chow with the same formulation, mice
were tested for AGS. Our results show that this oral administra-
tion of lovastatin significantly reduces AGS incidence (KO con
71%, KO lov 25%, *p = 0.003) and severity (KO veh versus lov
*p = 0.016) in the Fmr1 KO mouse (Figure 4D). These results
suggest that oral administration of pharmaceutical grade lova-
statin is effective in correcting AGS susceptibility in the Fmr1KO.Neuron 77, 243–250, January 23, 2013 ª2013 Elsevier Inc. 247
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Based on the insights that an ERK1/2 signaling pathway lies
upstream of the excessive hippocampal protein synthesis in
the Fmr1 KO (Osterweil et al., 2010) and that lovastatin can,
among other actions, inhibit Ras-ERK1/2 signaling in hippo-
campal neurons (Li et al., 2005), wewonderedwhether lovastatin
could correct core biochemical and electrophysiological conse-
quences of the loss of the translational repressor FMRP in FXS.
We thought this was a particularly exciting prospect because
lovastatin is widely prescribed, has a known safety profile, and
is approved for use in children (to treat hypercholesterolemia).
Our results show that lovastatin can indeed correct excessive
protein synthesis and prevent the emergence of epileptiform
activity in the Fmr1 KO hippocampus in vitro and can protect
the Fmr1 KO mice from AGS in vivo.
It has been suggested that seizures in children with develop-
mental disorders such as FXS could worsen the progression
and severity of other symptoms including autism (Berry-Kravis,
2002; Tuchman et al., 2010). Once manifest, seizures can be
controlled with conventional anticonvulsant medications, but
these drugs themselves have side effects that can exacerbate
other symptoms, such as cognitive impairment. Further, pro-
dromal changes may be as deleterious for brain development
as full-blown seizures. Therefore, preventing epileptogenesis is
an important goal.
Statins have been studied previously in rodent models of
epilepsy in which seizures are initiated or kindled in vivo by
administration of drugs or by direct electrical stimulation of the
temporal lobes. Some studies have suggested that statins can
lessen seizure activity (Lee et al., 2008; Ramirez et al., 2011;
Xie et al., 2011), whereas others have reported no effect (van
Vliet et al., 2011) or an exacerbation of seizures (Serbanescu
et al., 2004). Beneficial effects have typically been attributed to
reduced brain inflammation associated with seizures. In contrast
to previous work, we have used a genetically engineered mouse
model of FXS in which seizure phenotypes are not caused by
artificial induction of inflammatory responses and neurodegen-
eration. Our findings point to an entirely different mechanism of
action, by which lovastatin corrects multiple Fmr1 KO pheno-
types including, but not limited to, in vivo seizure activity by
downregulating Ras-ERK1/2 and protein synthesis.
It should be noted, however, that the connection between
seizure phenotypes in the mouse model and childhood epilepsy
in humans with FXS remains to be firmly established. For
example, AGS may be largely a reflex event driven by activation
of brainstem nuclei with limited relevance to cortical electroen-
cephalographic seizures (Raisinghani and Faingold, 2003).
Arguing against this point of view is the observation that audio
stimulation rapidly elicits (within 2 min) generalized tonic-clonic
seizures in most Fmr1 KO mice, showing that hyperexcitability
extends beyond brainstem neurons. Nevertheless, epileptogen-
esis in fragile X patients is manifest as the appearance of spon-
taneous seizures, which are not observed in the mouse model.
The issue of whether the pathogenesis of epilepsy is shared by
mice and humans lacking FMRP could be addressed if the
effects of a prophylactic treatment were compared in the two
species. Our findings that lovastatin, already approved for use248 Neuron 77, 243–250, January 23, 2013 ª2013 Elsevier Inc.in humans, can prevent epileptogenesis and hyperexcitability
in the Fmr1 KO suggest that carefully controlled human clinical
trials are warranted.
As a negative regulator of the mevalonate pathway, lova-
statin can impact the production of multiple compounds
involved in intracellular signaling, including ubiquinone, doli-
chol, and isoprenoids (Goldstein and Brown, 1990). Therefore,
we cannot rule out the possibility that some beneficial effects
of lovastatin could be due to actions other than the reduction
in Ras-ERK1/2 signaling, including a reduction in the farnesyla-
tion of other target proteins. However, like lovastatin, inhibitors
of Ras or ERK1/2 are sufficient to normalize protein synthesis,
and downregulation of the ERK1/2 pathway also blocks hippo-
campal epileptogenesis and eliminates AGS in the Fmr1 KO
(Chuang et al., 2005; Osterweil et al., 2010). Thus, although
the precise molecular mechanisms by which lovastatin confers
benefit remain to be determined, the weight of the evidence
suggests that the effects are due to a reduction in Ras-ERK1/
2 signaling.
This study was focused on the seizure phenotype because
it has both construct (genotypic) and face (phenotypic) validity
with the human disorder (with the caveats raised above).
However, previous work has suggested that multiple fragile X
symptoms can arise from the same core pathophysiology
(Bear et al., 2004; Bhakar et al., 2012). The finding that lovastatin
normalizes mGluR-LTD in the Fmr1 KO hippocampus to WT
levels (Figure 1F) is consistent with this idea. This result is
intriguing, however, as protein synthesis inhibitors cannot
correct the exaggerated mGluR-LTD in the Fmr1 KO (reviewed
in Bhakar et al., 2012). The implication is that lovastatin is exert-
ing additional beneficial effects on the Fmr1 KO beyond the
reduction of protein synthesis. What these effects are remains
to be determined; however, it should be noted that the selective
reduction of mGluR-LTD in the Fmr1 KO has been observed in
a previous study using lithium (Choi et al., 2011).
It will be of interest to assess in future studies the effect of lova-
statin treatment on the full spectrum of fragile X phenotypes.
Indeed, the findings that lovastatin can selectively quiet cortical
hyperexcitability in the Fmr1 KO (Figure 3) as well as exagger-
ated LTD suggest it could potentially improve sensory and
cognitive functions. Moreover, there is growing appreciation
that disruptions in Ras signaling (Krab et al., 2008) and synaptic
protein synthesis (Kelleher and Bear, 2008) may lie at the core of
many autisms of unknown etiology, suggesting that lovastatin
could have therapeutic utility in other ASDs as well as in other
symptom domains.EXPERIMENTAL PROCEDURES
Mice
Fmr1 KO (Jackson Laboratory) and WT littermates, bred on the C57BL/6 or
FVB background strains, were group housed and maintained in a 12:12 hr
light:dark cycle. All animals were treated in accordance with NIH, MIT, and
SUNY guidelines.
Metabolic Labeling
Experiments were performed on male WT and Fmr1 KO mice (postnatal days
25–32 [P25–P32]), blind to genotype, as described previously (Osterweil et al.,
2010). Details appear in Supplemental Experimental Prodecures.
Neuron
Lovastatin Corrects Pathophysiology in Fragile XImmunoblotting
Immunoblotting was performed blind to genotype and treatment, as described
previously (Osterweil et al., 2010), using primary antibodies to Ras (Pierce),
p-ERK1/2 (Thr202/Tyr204), ERK1/2, p-p70S6K (Thr389), p70S6K, p-S6
(Ser240/244), and S6 (Cell Signaling Technology) and HRP-conjugated
secondary antibodies (GE Healthcare).
Ras Activation Assay
Slices (four to six per animal) were prepared exactly as for metabolic labeling,
and Ras-GTP was isolated using the Active Ras Pull-Down and Detection kit
(Pierce) according to manufacturer’s instructions.
Hippocampal LTD
Experiments were performed blind to genotype, as described previously
(Huber et al., 2002). Lovastatin (50 mM) was dissolved in vehicle comprising
0.05% DMSO in ACSF. Slices were exposed to drug or vehicle from 30 min
prior to application of DHPG until the end of the experiment. Details appear
in Supplemental Experimental Procedures.
Hippocampal CA3 Recordings
Epileptiform activity was elicited using DHPG or bicuculline and intracellular
CA3 recordings were performed as previously described (Chuang et al.,
2005). Details appear in Supplemental Experimental Procedures.
Cortical Slice Electrophysiology
Slices of visual cortex were prepared from P16–P21 WT or Fmr1 KO animals,
blind to genotype, as described previously (Philpot et al., 2001). Submerged
slices were maintained at 30C in a modified ACSF that closely mimics phys-
iological CSF (124 mM NaCl, 3.5 mM KCl, 1.25 mM NaH2PO4, 26 vNaHCO3,
10 mM dextrose, 0.8 mM MgCl2, 1 mM CaCl2, saturated with 95% O2 and
5% CO2) and promotes spiking in response to electrical stimulation. Stimula-
tion electrodes (clustered bipolar tungsten, FHC) were positioned in white
matter and extracellular recordings were performed in layer 5 using glass
recording electrodes (1 MU). Baseline responses were collected every 30
s, using a stimulus intensity of 35–80 mA, 0.2 ms duration. Responses were
collected in ACSF plus vehicle, then ACSF + 50 mM lovastatin. Extracellular
recordings made using Axopatch 200B (Axon Instruments) were amplified
1,000 times, filtered between 0.3 and 3 Hz, and digitized at 25 kHz. Further
details are provided in Supplemental Experimental Procedures.
AGS
Experiments were performed using male WT and Fmr1 KO littermates (P17–
P25), blind to genotype, as described previously (Osterweil et al., 2010). For
acute exposure experiments, mice were injected i.p. with drug or vehicle
and returned to their home cages for 1 hr. For oral administration experiments,
mice were weaned onto standard rodent chow (Bio-serv) formulated with
100 mg/kg IC lovastatin (40 mg tablets, Mylan) or identical chow containing
no lovastatin and allowed to feed ad libitum for 48 hr. Immediately prior to
testing, mice were transferred to a quiet (<60 dB ambient sound) room for
1 hr, then transferred to a transparent plastic test chamber. After 1 min of
habituation, mice were exposed to a 130 dB stimulus (recorded sampling
of a modified personal alarm, Radioshack model 49-1010) for 2 min, and the
incidence and severity of AGS was scored. Further details are provided in
Supplemental Experimental Procedures.
SUPPLEMENTAL INFORMATION
Supplemental Information includes two figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.neuron.2012.01.034.
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